Claims for Patent: 7,610,097

Summary for Patent: 7,610,097

Title:	Electromagnetic stimulation in patients with osteoporosis
Abstract:	Provided is the combined use of pulsating electromagnetic signals and dose of Botulinum toxin to treat patients suffering from osteoporosis. Also provided is the use of electromagnetic signals generated by pulsating, impulse-modulated direct current for the treatment of osteoporosis.
Inventor(s):	Markoll; Richard (D-81925 Munchen, DE)
Assignee:
Application Number:	10/551,262
Patent Claims:	1. Method for treating osteoporosis in a patient, comprising: exposing the patient to electromagnetic signals generated by pulsating, impulse-modulated direct current, having a frequency of 1 to 30 Hz and a field strength of 1 to 20 G; and administering Botulinum toxin to the patient, wherein the Botulinum toxin synergistically interacts with the electromagnetic signals, by inducing a non-specific immune response to further enhance a bone density stimulation from the exposure of the patient to the electromagnetic signals. 2. Method according to claim 1, characterised in that the modulation form is quasi-rectangular. 3. Method according to claim 1, characterised in that the frequency is approximately 5 to 15 Hz. 4. Method according to claim 1, characterised in that the field strength is approximately 10 to 15 G. 5. Method according to claim 4, characterised in that the preferred field strength is approximately 12.5 G. 6. Method according to claim 1, characterised in that the pulses are modulated. 7. Method for administering a treatment to a patient including administration of a neurotoxin, the method comprising: providing a pharmaceutical composition comprising Botulinum toxin; administering the Botulinum toxin to the patient intramuscularly, intravenously, or subcutaneously; and exposing the patient to electromagnetic signals generated by pulsating, pulse-modulated, unidirectional, direct current, with frequency between 1 and 30 Hz and field strength, 1 to 20 G, wherein the Botulinum toxin synergistically interacts with the electromagnetic signals, by inducing a non-specific immune response to further enhance a bone density stimulation from the exposure of the patient to the electromagnetic signals. 8. Method according to claim 7, characterised in that the modulation form is quasi-rectangular. 9. Method according to claim 7, characterised in that the frequency is approximately 5 to 15 Hz. 10. Method according to claim 7, characterised in that the field strength is approximately 10 to 15 G. 11. Method according to claim 10, characterised in that the field strength is approximately 12.5 G. 12. Method according to claim 7, characterised in that the pulses are modulated. 13. Method according to claim 7, characterised by using a dose of Botulinum toxin Type A in the range of 20 U to 600 U, applied as a neurotoxin adjuvant to said exposing the patient to electromagnetic signals. 14. Method according to claim 7, characterised by using Botulinum toxin Type A in the range of 50 U to 300 U, applied as a neurotoxin adjuvant to said exposing the patient to electromagnetic signals. 15. Method according to claim 7, characterised by using Botulinum toxin Type B in the range 1 U to 2000 U, applied as a neurotoxin adjuvant to said exposing the patient to electromagnetic signals. 16. Method according to claim 1, characterised by using a dose of Botulinum toxin Type A in the range of 20 U to 600 U, applied as a neurotoxin adjuvant to said exposing the patient to electromagnetic signals. 17. Method according to claim 1, characterised by using a dose of Botulinum toxin Type A in the range of 50 U to 300 U, applied as a neurotoxin adjuvant to said exposing the patient to electromagnetic signals. 18. Method according to claim 1, characterised by using a dose of Botulinum toxin Type B in the range 1 U to 2000 U, applied as a neurotoxin adjuvant to said exposing the patient to electromagnetic signals. 19. Method according to claim 1, wherein a combination of exposing the patient to electromagnetic signals generated by pulsating, pulse-modulated, unidirectional direct current using Pulsed Signal Therapy (PST.RTM.) and administering Botulinum toxin enhances therapeutic benefit, including increase in bone mineral density (BMD) and a subsequent decrease in fracture risk. 20. Method according to claim 7, wherein a combination of exposing the patient to electromagnetic signals generated by pulsating, pulse-modulated, unidirectional direct current using Pulsed Signal Therapy (PST.RTM.) and administering Botulinum toxin enhances therapeutic benefit, including increase in bone mineral density (BMD) and a subsequent decrease in fracture risk.

Details for Patent 7,610,097

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	12/08/2000		2023-04-10